A New Immunotherapy Regimen for a Group of Rare Cancers
The immune checkpoint inhibitor durvalumab was approved in combination with chemotherapy for certain biliary tract cancers that have spread. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) in combination with the...